High Vista Strategies LLC Cyma Bay Therapeutics, Inc. Transaction History

High Vista Strategies LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.63 - $24.47 $252,233 - $488,690	-19,971 Reduced 11.08%	160,334 $3.79 Million
Q3 2023 Nov 14, 2023	SELL	$10.86 - $17.62 $1.72 Million - $2.79 Million	-158,537 Reduced 46.79%	180,305 $2.69 Million
Q2 2023 Aug 14, 2023	SELL	$7.47 - $10.95 $66,811 - $97,936	-8,944 Reduced 2.57%	338,842 $3.71 Million
Q1 2023 May 15, 2023	SELL	$5.88 - $9.59 $279,570 - $455,966	-47,546 Reduced 12.03%	347,786 $3.03 Million
Q2 2022 Aug 15, 2022	BUY	$1.72 - $3.39 $323,403 - $637,404	188,025 Added 90.7%	395,332 $1.17 Million
Q1 2022 May 16, 2022	BUY	$2.77 - $3.64 $574,240 - $754,597	207,307 New	207,307 $645,000
Q1 2021 May 17, 2021	SELL	$4.23 - $6.55 $492,875 - $763,199	-116,519 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$5.73 - $9.03 $667,653 - $1.05 Million	116,519 New	116,519 $669,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on High Vista Strategies LLC with notifications on news.